Drug Discovery World

JANUARY 23, 2023

Over the three days of Advanced Therapies Week (ATW) 2023 in Miami, Florida, US, from 18 to 20 January, DDW’s Megan Thomas heard from attendees about what they were most looking forward to learning from the event, as well as why they think the potential of cell and gene therapies outweighs the obstacles that must be overcome to achieve it.

Therapies 246

Therapies Small Molecule Production Treatment 246

Drug Discovery World

JUNE 26, 2024

There remains a significant unmet need for novel therapies that address the underlying synaptic pathology central to AD and our first-in-class, synaptogenic small molecule has the potential to provide a meaningful clinical impact. SPG302 has been granted FDA Orphan Drug Designation for the treatment of ALS.

Small Molecule 189

Small Molecule Pharmacokinetics Drugs Clinical Trials 189

Drug Discovery World

AUGUST 8, 2023

Astellas Pharma will invest $50 million into Poseida Therapeutics to secure the rights to the company’s cancer CAR-T cell therapy for solid tumours, which is currently in Phase I trials. ” Astellas’ portfolio includes oncolytic viruses, bispecific immune cell engagers, small molecules, and cell therapy platforms.

Therapies 130

Therapies Small Molecule Licensing Licensing 130

Drug Discovery World

FEBRUARY 19, 2024

Dr Julie Warner is Vice President of Regulatory Affairs at drug development consultancy, Boyds. In this article, she provides her expert insights into the key trends and developments expected to shape the global drug development industry this year. antibody-drug conjugate [ADC] pipelines in some oncology settings).

Drug Development 147

Drug Development Small Molecule Drugs Therapies 147

Drug Discovery World

AUGUST 16, 2024

Misetionamide is a tumour cell selective small molecule drug that is broadly active in multiple cancer models. Diana Spencer, Senior Digital Content Editor, DDW The post New data support antitumour drug misetionamide in ovarian cancers appeared first on Drug Discovery World (DDW).

Small Molecule 147

Small Molecule Drugs Clinical Trials Therapies 147

Drug Discovery World

DECEMBER 8, 2023

Andrew Busey , Co-Founder, Form Bio discusses why vertical AI is set to reshape the cell and gene therapy sector. The cell and gene therapy industry is no exception to this digital transformation. General AI tools such as ChatGPT have acted as a catalyst, igniting a wave of AI innovation akin to the early days of the internet era.

Therapies 162

Therapies Clinical Trials Small Molecule Production 162

Drug Discovery World

JUNE 7, 2023

Biotech company Shasqi and Johnson & Johnson have entered into a research collaboration to develop new cancer therapies. Shasqi’s Click Activated Protodrugs Against Cancer (CAPAC) platform relies on chemistry for activation of drugs at the tumour.

Therapies 130

Therapies Small Molecule Research Drugs 130

Drug Discovery World

JULY 18, 2024

The US Food and Drug Administration (FDA) has granted Fast Track designation to Sumitomo Pharma’s DSP-5336 for relapsed or refractory acute myeloid leukaemia (AML). The drug is intended for patients with a KMT2A rearrangement, also known as, mixed lineage leukaemia rearrangement (MLLr) or nucleophosmin mutation (NPM1m).

Small Molecule 130

Small Molecule FDA Drugs Therapies 130

Drug Discovery World

AUGUST 28, 2024

JT: We are developing novel small molecule, disease-modifying, allosteric regulators to treat serious diseases such as Parkinson’s disease and other dementias. Gain’s lead drug candidate GT-02287 is a best-in-class small molecule for the treatment of GBA-Parkinson’s disease and other neurodegenerative diseases.

Research 162

Research Small Molecule Disease Therapies 162

DrugBank

JULY 24, 2024

In the constantly evolving field of drug discovery, the term “undruggable” refers to proteins and targets in the body that, until recently, were considered impossible to treat with traditional drugs. These molecules are like finely tuned keys, fitting perfectly into their target proteins to disrupt harmful processes.

Small Molecule 84

Small Molecule Clinical Trials Drugs Therapies 84

Drug Discovery World

MARCH 15, 2024

Following the recent AD/PD 2024 conference, which took place on 5-9 March in Lisbon, Portugal, there have been a number of key announcements regarding investigational therapies for neurological disorders, particularly Alzheimer’s disease and Parkinson’s disease.

Small Molecule 130

Small Molecule Clinical Trials Drugs Trials 130

Drug Discovery World

FEBRUARY 12, 2024

DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. Cameron Ross, SVP, Generative AI, Elsevier “AI has the potential to dramatically shorten one of the most costly areas of early drug development – small molecule discovery.

Small Molecule 349

Small Molecule Regulations Clinical Trials Therapies 349

Drug Discovery World

MAY 31, 2024

The selected news highlights this week report breakthrough findings from early phase research and development, mainly preclinical studies and Phase I clinical trials, including a drug that can prevent sepsis deaths, a microbiome based immuno-oncology candidate, and a plant-based therapy for diarrhoea.

Small Molecule 130

Small Molecule Clinical Trials Drugs Trials 130

Drug Discovery World

JULY 19, 2024

TPD is a rapidly emerging field in drug development, exploiting a cell’s own destruction machinery to tackle disease-causing proteins that have historically been highly challenging to target with conventional therapies.

Targeted Protein Degradation 130

Targeted Protein Degradation Small Molecule Research Government 130

Drug Discovery World

JULY 19, 2024

This means that we rely on non-human, animal models to test drugs that can have effects on blood cell production and in targeting blood diseases (such as leukaemias). Diana Spencer, Senior Digital Content Editor, DDW The post New bone marrow model ‘big news’ for drug discovery appeared first on Drug Discovery World (DDW).

Small Molecule 130

Small Molecule Drugs Engineering Disease 130

Drug Discovery World

NOVEMBER 15, 2023

The small molecule, which binds to an inner region of a calcium channel to indirectly regulate it, outperformed gabapentin without troublesome side effects, providing a promising candidate for treating pain. A first-in-class small molecule Protein CRMP2 is a key regulator of the Cav2.2 The Cav2.2 (or

Small Molecule 130

Small Molecule Treatment Regulations Clinical Trials 130

Covalent Modifiers

FEBRUARY 6, 2024

Fibroblast growth factor receptor (FGFR) kinase inhibitors have been shown to be effective in the treatment of intrahepatic cholangiocarcinoma and other advanced solid tumors harboring FGFR2 alterations, but the toxicity of these drugs frequently leads to dose reduction or interruption of treatment such that maximum efficacy cannot be achieved.

Small Molecule 86

Small Molecule Treatment Science Therapies 86

Dark Matter Blog

AUGUST 27, 2020

A few years ago, at Arrakis Therapeutics, we set out to conquer a strange new territory, drugging RNA structures with small molecules. In fact, it was these early pharmaceutical successes that gave us the confidence that we would ultimately succeed in systematically drugging a wide range of RNA structures.

Small Molecule 52

Small Molecule RNA Clinical Trials Drugs 52

Drug Discovery World

DECEMBER 12, 2023

Exonate, an mRNA therapy company focused on treatments for diabetic complications, has announced that its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a Phase Ib/IIa study. During the trial, EXN407 met all safety and pharmacokinetic parameters and displayed encouraging signals of biological activity.

Small Molecule 130

Small Molecule Trials Pharmacokinetics Treatment 130

Drug Target Review

JULY 4, 2023

Over the last two decades, an increasing number of Antibody Drug Conjugate (ADC) therapeutics have been approved for oncology indications. These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

Drug Discovery World

FEBRUARY 13, 2024

Often this can be drug approvals, exciting research into hard-to-treat indications, or even regulatory updates that enable players within the sector to utilise the latest technologies and drive therapies to market faster, ultimately benefitting patients. But is AI the answer to the industry’s development challenges?

Small Molecule 147

Small Molecule Drugs Therapies Pharmaceutical Companies 147

Drug Discovery World

MARCH 10, 2023

Perhaps most interestingly this week, after previous caution over in vivo gene therapy trials, the FDA has given the go ahead to Intellia Therapeutics to study NTLA-2002 in hereditary angioedema (HAE). The post This week in drug discovery (6-10 March) appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Small Molecule Trials Drugs 130

The Pharma Data

JANUARY 19, 2021

Precision medicine developer Kura Oncology is positioned to make a meaningful difference in the treatment of cancer in the next few years with its two, wholly-owned, small molecule compounds. As with any innovative therapy, “It takes multiple iterations and time to get things right,” he pointed out. “We Photo courtesy of Kura.

Small Molecule 52

Small Molecule Therapies FDA Approval Trials 52

Drug Discovery World

AUGUST 18, 2023

My chosen news stories this week all discuss pre-clinical research studies that could have a huge impact on our therapeutic approach to several hard-to-treat diseases, helping to overcome drug-resistance and make treatments more targeted in the future.

Small Molecule 130

Small Molecule Virus Drugs Clinical Research 130

Broad Institute

NOVEMBER 2, 2023

Bayer and Broad Institute extend cancer therapy research collaboration By Corie Lok November 2, 2023 Breadcrumb Home Bayer and Broad Institute extend cancer therapy research collaboration Long-standing industry-academia collaboration has already resulted in three clinical oncology candidates.

Therapies 105

Therapies Research Small Molecule Clinical Trials 105

Drug Discovery World

OCTOBER 21, 2022

While advances in treatment over the last few years have resulted in good overall survival rates for patients with non-metastatic disease (90% five-year survival rate in the US 1 ), outcomes are still poor in certain cancers that do not respond to standard therapies. 3D bioprinted breast cancer tumours.

Therapies 130

Therapies Small Molecule Immune Response Engineering 130

Drug Discovery World

MAY 24, 2023

million to develop the next generation of small molecule drugs against disease areas of high clinical need. The aim is to develop therapies with fewer side effects to treat diseases with a high clinical need. investment to target cancer and neurological diseases appeared first on Drug Discovery World (DDW).

Small Molecule 130

Small Molecule Disease Therapies Treatment 130

Drug Discovery World

SEPTEMBER 4, 2024

EVO756 is a highly selective small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2) and could offer the potential for once-daily oral administration without the side effects observed with other therapies.

Clinical Trials 130

Clinical Trials Trials Small Molecule Clinical Development 130

Drug Discovery World

MAY 30, 2024

A new research paper has validated the mechanism of action of the Atrogi’s first-in-class, small molecule, ATR-127, in combating obesity and metabolic complications. Unlike existing anti-obesity therapies that compromise lean muscle mass, ATR-127 induces significant weight loss while preserving crucial lean body mass.

Small Molecule 147

Small Molecule Treatment International Production 147

Drug Target Review

JUNE 19, 2024

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. In some cases, cell therapy can be curative for the patient.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

DrugBank

MAY 15, 2024

The road to developing effective drugs is fraught with both promise and challenge, particularly when it comes to what scientists call "undruggable" targets. The Evolution of Drug Discovery: From Dark Rooms to Precision Targets In the past, drug discovery often felt like a lucky guess.

Small Molecule 83

Small Molecule Molecular Biology Drugs Disease 83

Drug Discovery World

MARCH 15, 2024

Biotechnology company Allyx Therapeutics has reported positive Phase Ib clinical data for its lead compound, ALX-001, a first-in-class, synapse-targeted, disease-modifying oral therapy in development for neurodegenerative diseases. The findings were presented at the AD/PD 2024 Conference in Lisbon.

Disease 130

Disease Trials Small Molecule Pharmacokinetics 130

Drug Discovery World

SEPTEMBER 29, 2023

From identifying novel targets to simulating how drugs will function in the human body, Clarivate says the companies are combining innovative technologies with therapeutic area expertise and data sets of partners to make incredible strides in the space. Enveda Biosciences – focuses on the natural world for drug discovery.

Small Molecule 130

Small Molecule Drugs Therapies Disease 130

Drug Discovery World

DECEMBER 26, 2023

Otsuka Pharmaceutical and Ionis Pharmaceuticals Otsuka Pharmaceutical and RNA therapy company Ionis have entered into a licence agreement for Otsuka to acquire exclusive marketing rights to Ionis’ hereditary angioedema (HAE) drug candidate donidalorsen in Europe. Ionis is currently conducting two Phase III multicentre studies.

Small Molecule 130

Small Molecule Drugs Molecular Biology Bioinformatics 130

Drug Discovery World

MARCH 12, 2024

DDW’s Megan Thomas speaks to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. Amanda Halford, President Bioprocess, Cytiva “In 2024, the emphasis will remain on novel mAbs, specifically antibody drug conjugates. This is part of a series of predictions based on different themes.

Molecular Biology 204

Molecular Biology Small Molecule Therapies FDA Approval 204

Drug Discovery World

OCTOBER 19, 2022

Reece Armstrong speaks to Natalia Mateu, Co-Founder, Jelena Aleksic, Co-Founder and Peter Curran, Chemoinformatics Scientist, about utilising 3D chemistry and AI to get small molecule therapies from the clinic to the bedside. RA: How is Pharmenable aiming to replicate the specificity of biologics in small molecule drugs?

Small Molecule 130

Small Molecule Therapies Drugs 130

Drug Discovery World

MAY 26, 2023

The top stories: Biopharma investment drops by nearly 50% in 2022 Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. million to develop the next generation of small molecule drugs against disease areas of high clinical need.

Small Molecule 130

Small Molecule DNA Government RNA 130